146 related articles for article (PubMed ID: 36820561)
1. The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes.
Kayikcioglu E; Yüceer RO
Medicine (Baltimore); 2023 Feb; 102(6):e32882. PubMed ID: 36820561
[TBL] [Abstract][Full Text] [Related]
2. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients.
Zhang Z; Liu X; Zhou L; Zhang M; Liang Z
Histol Histopathol; 2022 Oct; 37(10):1031-1040. PubMed ID: 35656795
[TBL] [Abstract][Full Text] [Related]
3. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma.
Wang X; Zhang CS; Dong XY; Hu Y; Duan BJ; Bai J; Wu YY; Fan L; Liao XH; Kang Y; Zhang P; Li MY; Xu J; Mao ZJ; Liu HT; Zhang XL; Tian LF; Li EX
World J Gastrointest Oncol; 2022 Jul; 14(7):1252-1264. PubMed ID: 36051096
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression.
Park S; Shin K; Kim IH; Hong T; Kim Y; Suh J; Lee M
J Clin Med; 2023 Aug; 12(16):. PubMed ID: 37629433
[TBL] [Abstract][Full Text] [Related]
5. Claudin-18 is an early-stage marker of pancreatic carcinogenesis.
Tanaka M; Shibahara J; Fukushima N; Shinozaki A; Umeda M; Ishikawa S; Kokudo N; Fukayama M
J Histochem Cytochem; 2011 Oct; 59(10):942-52. PubMed ID: 21832145
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.
Kayikcioglu E; Yüceer RO; Cetin B; Yüceer K; Karahan N
World J Gastrointest Oncol; 2023 Feb; 15(2):343-351. PubMed ID: 36908327
[TBL] [Abstract][Full Text] [Related]
7. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms.
Wöll S; Schlitter AM; Dhaene K; Roller M; Esposito I; Sahin U; Türeci Ö
Int J Cancer; 2014 Feb; 134(3):731-9. PubMed ID: 23900716
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical study of claudin 18 involvement in intestinal differentiation during the progression of intraductal papillary mucinous neoplasm.
Sanada Y; Hirose Y; Osada S; Tanaka Y; Takahashi T; Yamaguchi K; Yoshida K
Anticancer Res; 2010 Jul; 30(7):2995-3003. PubMed ID: 20683045
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological significance and prognostic role of chemokine receptor CXCR4 expression in pancreatic ductal adenocarcinoma, a meta-analysis and literature review.
Ding Y; Du Y
Int J Surg; 2019 May; 65():32-38. PubMed ID: 30902754
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells.
Ito T; Kojima T; Yamaguchi H; Kyuno D; Kimura Y; Imamura M; Takasawa A; Murata M; Tanaka S; Hirata K; Sawada N
J Cell Biochem; 2011 Jul; 112(7):1761-72. PubMed ID: 21381080
[TBL] [Abstract][Full Text] [Related]
11. RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients.
Pereira MA; Ramos MFKP; Dias AR; Cardili L; Ribeiro RRE; de Castria TB; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES
Med Sci (Basel); 2021 Dec; 10(1):. PubMed ID: 35076580
[No Abstract] [Full Text] [Related]
12. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).
Le K; Wang J; Zhang T; Guo Y; Chang H; Wang S; Zhu B
Int J Med Sci; 2020; 17(4):422-427. PubMed ID: 32174772
[No Abstract] [Full Text] [Related]
13. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study.
Dottermusch M; Krüger S; Behrens HM; Halske C; Röcken C
Virchows Arch; 2019 Nov; 475(5):563-571. PubMed ID: 31332522
[TBL] [Abstract][Full Text] [Related]
14. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
15. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
Dai J; Zheng H; Jin J; Cheng Y; Xu H
Cancer Cytopathol; 2023 Jun; 131(6):365-372. PubMed ID: 36793190
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
Baek JH; Park DJ; Kim GY; Cheon J; Kang BW; Cha HJ; Kim JG
Anticancer Res; 2019 Dec; 39(12):6973-6979. PubMed ID: 31810969
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients with pancreatic ductal adenocarcinoma.
Jiang B; Zhou L; Lu J; Wang Y; Liu C; Liang Z; Zhou W; You L; Guo J
J Gastroenterol Hepatol; 2021 Feb; 36(2):507-515. PubMed ID: 32875609
[TBL] [Abstract][Full Text] [Related]
18. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
19. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
20. Low expression of tRF-Pro-CGG predicts poor prognosis in pancreatic ductal adenocarcinoma.
Li J; Jin L; Gao Y; Gao P; Ma L; Zhu B; Yin X; Sui S; Chen S; Jiang Z; Zhu C
J Clin Lab Anal; 2021 May; 35(5):e23742. PubMed ID: 33675071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
